Royalty Pharma RPRX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | 294.6%+84.5pp | 210.1%— | —— | —— | |
| Net margin | 157.7%+3.4pp | 154.3%— | —— | —— | |
| Returns | |||||
| Return on equity | 37.2%+2.2pp | 34.9%— | —— | —— | |
| Return on invested capital | 41.2%+11.0pp | 30.2%— | —— | —— | |
| Efficiency | |||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.6×0.0× | 0.5×— | |
| Liquidity | |||||
| Current ratio | 8.7×-16.1× | 24.8×-1.4× | 26.3×-19.1× | 45.4×-1.2× | |
| Leverage | |||||
| Debt-to-equity | 3.5×+0.6× | 2.9×+0.2× | 2.7×-0.1× | 2.8×+0.3× | |
| Per Share | |||||
| Book value per share | $68.22+1.0% | $67.56+3.9% | $65.04-10.6% | $72.75-3.2% | |
| Valuation | |||||
| Market capitalization | $60.48B+22.2% | $49.5B-9.1% | $54.48B-22.5% | $70.3B+1.9% | |
| Price / earnings | 68.5×+9.6× | 59×— | —— | —— | |
| Price / sales | 26×+4.0× | 22×-1.2× | 23.2×-8.0× | 31.2×+0.5× | |
| Price / book | 6.3×+1.3× | 4.9×-0.6× | 5.5×-1.4× | 7×+0.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Royalty Pharma's ratios come from?
- Every ratio is computed from Royalty Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
